Trichome

thcscience_admin
PPARD
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesPPARD, FAAR, NR1C2, NUC1, NUCI, NUCII, PPARB, peroxisome proliferator activated receptor delta
External IDsOMIM: 600409 MGI: 101884 HomoloGene: 4544 GeneCards: PPARD
Orthologs
SpeciesHumanMouse
Entrez

5467

19015

Ensembl

ENSG00000112033

ENSMUSG00000002250

UniProt

Q03181

P35396

RefSeq (mRNA)

NM_001171818
NM_001171819
NM_001171820
NM_006238
NM_177435

NM_011145

RefSeq (protein)

NP_001165289
NP_001165290
NP_001165291
NP_006229
NP_803184

NP_035275

Location (UCSC)Chr 6: 35.34 – 35.43 MbChr 17: 28.23 – 28.3 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Peroxisome proliferator-activated receptor delta (PPAR-delta), or (PPAR-beta), also known as Nuclear hormone receptor 1 (NUC1) is a nuclear receptor that in humans is encoded by the PPARD gene.[5]

This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) family. It was first identified in Xenopus in 1993.[6]

Function[edit]

PPAR-delta is a nuclear hormone receptor that governs a variety of biological processes and may be involved in the development of several chronic diseases, including diabetes, obesity, atherosclerosis, and cancer.[7][8]

In muscle PPARD expression is increased by exercise, resulting in increased oxidative (fat-burning) capacity and an increase in type I fibers.[9] Both PPAR-delta and AMPK agonists are regarded as exercise mimetics.[10] In adipose tissue PPAR-β/δ increases both oxidation as well as uncoupling of oxidative phosphorylation.[9]

PPAR-delta may function as an integrator of transcription repression and nuclear receptor signaling. It activates transcription of a variety of target genes by binding to specific DNA elements. Well described target genes of PPARδ include PDK4, ANGPTL4, PLIN2, and CD36. The expression of this gene is found to be elevated in colorectal cancer cells.[11] The elevated expression can be repressed by adenomatosis polyposis coli (APC), a tumor suppressor protein involved in the APC/beta-catenin signaling pathway. Knockout studies in mice suggested the role of this protein in myelination of the corpus callosum, epidermal cell proliferation, and glucose[12] and lipid metabolism.[13]

This protein has been shown to be involved in differentiation, lipid accumulation,[14] directional sensing, polarization, and migration in keratinocytes.[15]

Role in cancer[edit]

Studies into the role of PPAR-delta in cancer have produced contradictory results. Although there is some controversy, the majority of studies have suggested that PPAR-delta activation could result in changes that are favorable to cancer progression.[16] PPAR-delta favours tumour angiogenesis.[17]

Tissue distribution[edit]

PPAR-delta is highly expressed in many tissues, including colon, small intestine, liver and keratinocytes, as well as in heart, spleen, skeletal muscle, lung, brain and thymus.[18]

Knockout studies[edit]

Knockout mice lacking the ligand binding domain of PPAR-delta are viable. However, these mice are smaller than the wild type both neo and postnatally. In addition, fat stores in the gonads of the mutants are smaller. The mutants also display increased epidermal hyperplasia upon induction with TPA.[19]

Ligands[edit]

PPAR-delta is activated in the cell by various fatty acids and fatty acid derivatives.[7] Examples of naturally occurring fatty acids that bind with and activate PPAR-delta include arachidonic acid and certain members of the 15-hydroxyicosatetraenoic acid family of arachidonic acid metabolites including 15(S)-HETE, 15(R)-HETE, and 15-HpETE.[20] Several high affinity ligands for PPAR-delta have been developed, including GW501516 and GW0742, which play an important role in research. In one study utilizing such a ligand, it has been shown that agonism of PPARδ changes the body's fuel preference from glucose to lipids.[21] Initially, PPAR-delta agonists were considered promising therapies as an exercise mimetic that could treat metabolic syndrome, but later on more evidence was uncovered about their possible pro-cancer effects.[16]

Agonists[edit]

Although its drug development was discontinued due to animal studies suggesting an increased risk of cancer, GW501516 has been used as a performance enhancing drug.[24] It and other PPAR-delta agonists are banned in sports.[25][26]

Interactions[edit]

Peroxisome proliferator-activated receptor delta has been shown to interact with HDAC3[27][28] and NCOR2.[28]

References[edit]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000112033 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000002250 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA (October 1992). "Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids". Molecular Endocrinology. 6 (10): 1634–1641. doi:10.1210/mend.6.10.1333051. PMID 1333051. S2CID 23506853.
  6. ^ Krey G, Keller H, Mahfoudi A, Medin J, Ozato K, Dreyer C, Wahli W (December 1993). "Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids". The Journal of Steroid Biochemistry and Molecular Biology. 47 (1–6): 65–73. doi:10.1016/0960-0760(93)90058-5. PMID 8274443. S2CID 25098754.
  7. ^ a b Berger J, Moller DE (2002). "The mechanisms of action of PPARs". Annual Review of Medicine. 53: 409–435. doi:10.1146/annurev.med.53.082901.104018. PMID 11818483.
  8. ^ Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (March 2006). "From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions". Progress in Lipid Research. 45 (2): 120–159. doi:10.1016/j.plipres.2005.12.002. PMID 16476485.
  9. ^ a b Giordano Attianese GM, Desvergne B (2015). "Integrative and systemic approaches for evaluating PPARβ/δ (PPARD) function". Nuclear Receptor Signaling. 13: e001. doi:10.1621/nrs.13001. PMC 4419664. PMID 25945080.
  10. ^ Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM (August 2008). "AMPK and PPARdelta agonists are exercise mimetics". Cell. 134 (3): 405–415. doi:10.1016/j.cell.2008.06.051. PMC 2706130. PMID 18674809.
  11. ^ Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, Tsujino T, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M (October 2006). "Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology". British Journal of Cancer. 95 (7): 889–895. doi:10.1038/sj.bjc.6603343. PMC 2360534. PMID 16969348.
  12. ^ Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM (February 2006). "PPARdelta regulates glucose metabolism and insulin sensitivity". Proceedings of the National Academy of Sciences of the United States of America. 103 (9): 3444–3449. Bibcode:2006PNAS..103.3444L. doi:10.1073/pnas.0511253103. PMC 1413918. PMID 16492734.
  13. ^ "Entrez Gene: PPARD peroxisome proliferator-activated receptor delta".
  14. ^ Schmuth M, Haqq CM, Cairns WJ, Holder JC, Dorsam S, Chang S, Lau P, Fowler AJ, Chuang G, Moser AH, Brown BE, Mao-Qiang M, Uchida Y, Schoonjans K, Auwerx J, Chambon P, Willson TM, Elias PM, Feingold KR (April 2004). "Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes". The Journal of Investigative Dermatology. 122 (4): 971–983. doi:10.1111/j.0022-202X.2004.22412.x. PMID 15102088.
  15. ^ Tan NS, Icre G, Montagner A, Bordier-ten-Heggeler B, Wahli W, Michalik L (October 2007). "The nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, polarization, and migration". Molecular and Cellular Biology. 27 (20): 7161–7175. doi:10.1128/MCB.00436-07. PMC 2168901. PMID 17682064.
  16. ^ a b Wagner N, Wagner KD (May 2020). "PPAR Beta/Delta and the Hallmarks of Cancer". Cells. 9 (5): 1133. doi:10.3390/cells9051133. PMC 7291220. PMID 32375405.
  17. ^ Wagner KD, Du S, Martin L, Leccia N, Michiels JF, Wagner N (December 2019). "Vascular PPARβ/δ Promotes Tumor Angiogenesis and Progression". Cells. 8 (12): 1623. doi:10.3390/cells8121623. PMC 6952835. PMID 31842402.
  18. ^ Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM (July 2008). "Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice". Biochemical and Biophysical Research Communications. 371 (3): 456–461. doi:10.1016/j.bbrc.2008.04.086. PMC 2586836. PMID 18442472.
  19. ^ Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ (July 2000). "Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)". Molecular and Cellular Biology. 20 (14): 5119–5128. doi:10.1128/MCB.20.14.5119-5128.2000. PMC 85961. PMID 10866668.
  20. ^ Mol. Pharmacol. 77:171-184, 2010
  21. ^ Brunmair B, Staniek K, Dörig J, Szöcs Z, Stadlbauer K, Marian V, Gras F, Anderwald C, Nohl H, Waldhäusl W, Fürnsinn C (November 2006). "Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids". Diabetologia. 49 (11): 2713–2722. doi:10.1007/s00125-006-0357-6. PMID 16960684.
  22. ^ van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, Staels B, Groot PH, Groen AK, Kuipers F (March 2005). "Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1". Journal of Lipid Research. 46 (3): 526–534. doi:10.1194/jlr.M400400-JLR200. PMID 15604518. S2CID 261023817.
  23. ^ Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JP, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DE, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA (August 2023). "Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study". Hepatology. 78 (2): 397–415. doi:10.1097/HEP.0000000000000395. PMC 10344437. PMID 37386786.
  24. ^ Koh B (22 March 2013). "Anti-doping agency warns cheats on the health risks of Endurobol". The Conversation. Retrieved 5 September 2023.
  25. ^ Trevisiol S, Moulard Y, Delcourt V, Jaubert M, Boyer S, Tendon S, Haryouli H, Taleb W, Caroff M, Chabot B, Drif L, André F, Garcia P, Loup B, Popot MA, Bailly-Chouriberry L (June 2021). "Comprehensive characterization of the peroxisome proliferator activated receptor-δ agonist GW501516 for horse doping control analysis". Drug Testing and Analysis. 13 (6): 1191–1202. doi:10.1002/dta.3013. PMID 33547737. S2CID 231899376.
  26. ^ Sobolevsky T, Dikunets M, Sukhanova I, Virus E, Rodchenkov G (October 2012). "Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine". Drug Testing and Analysis. 4 (10): 754–760. doi:10.1002/dta.1413. PMID 22977012.
  27. ^ Franco PJ, Li G, Wei LN (August 2003). "Interaction of nuclear receptor zinc finger DNA binding domains with histone deacetylase". Molecular and Cellular Endocrinology. 206 (1–2): 1–12. doi:10.1016/S0303-7207(03)00254-5. PMID 12943985. S2CID 19487189.
  28. ^ a b Shi Y, Hon M, Evans RM (March 2002). "The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling". Proceedings of the National Academy of Sciences of the United States of America. 99 (5): 2613–2618. Bibcode:2002PNAS...99.2613S. doi:10.1073/pnas.052707099. PMC 122396. PMID 11867749.

Further reading[edit]

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

source: https://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor_delta

Leave a Reply